ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant

Summary

This is a single-center Phase 1 trial of 20 patients with AML/MDS. Eligible patients will be enrolled following an informed consent between 6-20 weeks after allogeneic hematopoietic stem cell transplant. Patients will receive weekly oral ONC 201 for a total of 52 weeks.

Timeline

Start

2019-07-30

Primary completion

2025-03-27

Completion

2025-03-27

Publications

• Bhatt VR, Wichman CS, Bouska A, Ellithi M, Haddadin M, Iqbal J, Talmadge JE, Maness LJ, Gundabolu K. Dordaviprone Maintenance After Allogeneic HCT for High-Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm. Am J Hematol. 2026 Jun 26. doi: 10.1002/ajh.70428. Online ahead of print.

Drugs

Indications